Women at risk of ovarian cancer and who are undergoing hysterectomy should be counseled about the possible benefits of salpingectomy, according to a new committee opinion from the American College of Obstetricians and Gynecologists.
Women at risk of ovarian cancer and who are undergoing hysterectomy should be counseled about the possible benefits of salpingectomy, according to a new committee opinion from the American College of Obstetricians and Gynecologists (ACOG). The discussion, however, should not influence the choice of surgical approach for hysterectomy or for sterilization.
Dr. Lockwood's top 10 resolutions for 2015
ACOG Committee Opinion Number 620 underscores the high mortality rate of ovarian cancer, which is the fifth leading cause of cancer deaths in women, and the lack of effective diagnostics for the disease. Researchers theorize that retrograde menses may cause endometrioid and clear cell carcinomas of the ovary, hence the potentially protective effect of salpingectomy.
The authors of the Committee Opinion note the safety of salpingectomy, the lack of impact of the procedure on ovarian function, and the value of discussing bilateral salpingectomy as a method of contraception. They also emphasize the need for randomized controlled trials to validate a reduction in incidence of ovarian cancer as a result of salpingectomy in selected patients.
In concluding, the authors indicate that “the approach to hysterectomy or sterilization should not be influenced by the theoretical benefit of salpingectomy. Surgeons should continue to observe and practice minimally invasive techniques. A vaginal hysterectomy should not be changed to a laparoscopic hysterectomy simply to perform a salpingectomy.”
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More